Basilea Pharmaceutica (XSWX:BSLN) Selling, General, & Admin. Expense: CHF35.6 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
58 GF Score
Price CHF52.30
GF Value CHF57.87
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Selling, General, & Admin. Expense?

Basilea Pharmaceutica XSWX:BSLN 58 Selling, General, & Admin. Expense is CHF35.6 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 58/100 and a GF Value™ of CHF57.87 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Basilea Pharmaceutica's selling, general, & admin. expense for the six months ended in Dec. 2025 was CHF18.2 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF35.6 Mil.


Basilea Pharmaceutica  (XSWX:BSLN) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Basilea Pharmaceutica Selling, General, & Admin. Expense Related Terms


Basilea Pharmaceutica Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Selling, General, & Admin. Expense Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.72 30.82 33.78 31.54 35.62

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.24 15.32 16.22 17.40 18.21

XSWX:BSLN vs VRTX, REGN, ALNY: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Selling, General, & Admin. Expense falls into.


XSWX:BSLN
58GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF35.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of CHF35.6 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Selling, General, & Admin. Expense of CHF35.6 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Selling, General, & Admin. Expense too high?
Basilea Pharmaceutica's current Selling, General, & Admin. Expense is CHF35.6 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Selling, General, & Admin. Expense compare to VRTX and REGN?
Basilea Pharmaceutica's Selling, General, & Admin. Expense of CHF35.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Selling, General, & Admin. Expense is CHF35.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.87, compared to a current price of CHF52.30 — trading 9.6% below its estimated fair value. The current Selling, General, & Admin. Expense is CHF35.6 Mil. Basilea Pharmaceutica's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Selling, General, & Admin. Expense is CHF35.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF52.30 is trading 9.6% below its estimated GF Value™ of CHF57.87. GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.

Key valuation signals for XSWX:BSLN:

  • Selling, General, & Admin. Expense: CHF35.6 Mil
  • GF Value™: CHF57.87 vs. price of CHF52.30 (9.6% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
58GF Score

Get the complete analysis for XSWX:BSLN

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF52.30
Price
CHF57.87
GF Value